CLPT:NSD-ClearPoint Neuro, Inc (USD)

COMMON STOCK | Medical Devices | NSD

Last Closing Price

USD 22.12

Change

-0.43 (-1.91)%

Market Cap

USD 0.44B

Volume

0.30M

Average Target Price

USD 24.30 (+9.86%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system, a neuro-navigation system designed for instruments or devices designed to treat various neurological diseases and conditions, as well as for performing biopsies. In addition, the company's product pipeline includes ClearTrace system, a product candidate designed to perform minimally invasive surgical procedures in the heart. It has license and collaboration agreements with The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Microsystems, LLC, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Irvine, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-04-09 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ALGN Align Technology, Inc

+16.81 (+2.92%)

USD45.56B 25.69 87.90
PODD Insulet Corporation

+2.57 (+0.90%)

USD18.40B 2,785.00 159.67
ABMD Abiomed, Inc

+4.06 (+1.23%)

USD14.62B 73.68 55.53
LVGO Livongo Health, Inc

N/A

USD14.20B N/A N/A
BRKR Bruker Corporation

+1.16 (+1.72%)

USD10.21B 66.02 32.46
IART Integra LifeSciences Holdings ..

+0.65 (+0.94%)

USD5.86B 44.25 24.70
TNDM Tandem Diabetes Care, Inc

-0.01 (-0.01%)

USD5.50B N/A N/A
SWAV ShockWave Medical, Inc

-0.98 (-0.71%)

USD4.60B N/A N/A
AHCO AdaptHealth Corp

+0.27 (+0.72%)

USD4.32B -99,999.99 96.44
SDC SmileDirectClub, Inc

+0.01 (+0.10%)

USD3.90B N/A N/A

ETFs Containing CLPT

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 59.94% 81% B- 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 59.94% 81% B- 90% A-
Trailing 12 Months  
Capital Gain 548.68% 97% A+ 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 548.68% 97% A+ 95% A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 45.10% 80% B- 86% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 45.10% 80% B- 86% B
Risk Return Profile  
Volatility (Standard Deviation) 130.06% 14% F 10% F
Risk Adjusted Return 34.68% 57% F 58% F
Market Capitalization 0.44B 54% F 48% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -99,999.99 88% B+ 97% A+
Price/Book Ratio 195.68 2% F 1% F
Price / Cash Flow Ratio -56.98 87% B+ 91% A-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -194.80% 15% F 6% F
Return on Invested Capital -41.03% 40% F 20% F
Return on Assets -18.76% 37% F 20% F
Debt to Equity Ratio 895.25% 2% F 1% F
Technical Ratios  
Short Ratio 0.46 81% B- 78% C+
Short Percent 1.77% 87% B+ 69% D+
Beta 1.04 56% F 58% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.